NCT05417087View on ClinicalTrials.gov

Single Dose Oral Bioequivalence Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

PHASE1CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

June 27, 2022

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions
Major Depressive Disorder (MDD)
Interventions
DRUG

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets

Vortioxetine Hemihydrobromide Orally Disintegrating Tablets 20 mg equivalent to 20 mg of Vortioxetine

DRUG

Vortioxetine Hydrobromide Tablets

Vortioxetine Hydrobromide Tablets 20mg

Trial Locations (1)

382210

Cliantha Research Limited, Ahmedabad

All Listed Sponsors
lead

Seasons Biotechnology (Taizhou) Co., Ltd.

INDUSTRY